this is a Phase 3, global, multicenter, randomized, open-label, controlled study
to compare the efficacy and safety of DOM+ ZIM in combination with chemotherapy relative
to PEMBRO in combination with chemotherapy in participants with metastatic non–small cell
lung cancer (NSCLC) with no epidermal growth factor receptor (EGFR) or anaplastic
lymphoma kinase (ALK) genomic tumor aberrations who have not received previous systemic
therapy for metastatic disease.

domvanalimab (DOM) +
zimberelimab (ZIM) in combination with chemotherapy
relative to pembrolizumab (PEMBRO) in combination with
chemotherapy (Group A versus Group B)

1. Participants assigned male at birth and participants assigned female at birth, 18 years of
   age or older, able to understand and give written informed consent.
2. Life expectancy ≥ 3 months.
3. Pathologically documented NSCLC that meets both criteria below:
   a) Have documented evidence of Stage IV NSCLC disease at the time of enrollment
   (based on AJCC, Eighth Edition).
   b) Have documented negative test results for EGFR and ALK mutations.
   Note: tumor testing for EGFR or ALK mutations is required for participants with
   nonsquamous NSCLC tumor histology if status is unknown (Section 6.3.9).
4. Have no actionable genomic alterations such as ROS proto-oncogene 1, neurotrophic
   tyrosine receptor kinase, proto-oncogene B-raf, RET mutations, or other driver oncogenes
   with approved frontline therapies. Testing of actionable genomic alterations required by
   local regulations will be performed locally.
5. Provide adequate tumor tissue from locations not radiated prior to biopsy to evaluate
   PD-L1 expression prior to randomization. Bone biopsies, cytology, and fine needle
   aspirates are not suitable tissues. If no tissue is available, a new biopsy will need to be
   obtained prior to enrollment in the study.
6. Have not received prior systemic treatment for metastatic NSCLC. Participants who
   received chemotherapy for nonmetastatic disease are eligible if the treatment was
   completed at least 12 months prior to the start of study treatment.
7. Measurable disease per RECIST v1.1 criteria by investigator assessment (Appendix 7).
   Tumor lesions situated in a previously irradiated area are considered measurable if
   progression has been demonstrated in such lesions.
8. ECOG performance status score of 0 or 1."

1. Have mixed small-cell lung cancer and NSCLC histology.
2. Positive serum pregnancy test or participants who are breastfeeding or have plans to
   breastfeed during the study period and for the required duration of contraception use after
   the last dose of study drug.
3. Received prior treatment with any anti-programmed cell death protein 1, anti-PD-L1, or
   any other antibody targeting an immune checkpoint. Participants who received
   programmed cell death protein 1/programmed cell death ligand 1 inhibitors as a part of
   treatment for early stage or locally advanced NSCLC are not eligible.
4. Known hypersensitivity to the study drug, its metabolites, or formulation excipient."